573 related articles for article (PubMed ID: 34401884)
21. Covid-19 Rates by Time since Vaccination during Delta Variant Predominance.
Paz-Bailey G; Sternberg M; Kugeler K; Hoots B; Amin AB; Johnson AG; Barbeau B; Bayoumi NS; Bertolino D; Boulton R; Brown CM; Busen K; Cima M; Drenzek C; Gent A; Haney G; Hicks L; Hook S; Jara A; Jones A; Kamal-Ahmed I; Kangas S; Kanishka FNU; Khan SI; Kirkendall SK; Kocharian A; Lyons BC; Lauro P; McCormick D; McMullen C; Milroy L; Reese HE; Sell J; Sierocki A; Smith E; Sosin D; Stanislawski E; Strand K; Troelstrup T; Turner KA; Vest H; Warner S; Wiedeman C; Silk B; Scobie HM
NEJM Evid; 2022 Jan; 1(3):. PubMed ID: 37207114
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
[TBL] [Abstract][Full Text] [Related]
23. Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
Mancuso M; Eikenberry SE; Gumel AB
Infect Dis Model; 2021; 6():1110-1134. PubMed ID: 34518808
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance.
Islam N; Griffin DO; Jarvis MS; Cohen K
Heliyon; 2023 May; 9(5):e16006. PubMed ID: 37163164
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants.
Kislaya I; Rodrigues EF; Borges V; Gomes JP; Sousa C; Almeida JP; Peralta-Santos A; Nunes B;
Emerg Infect Dis; 2022 Feb; 28(2):331-337. PubMed ID: 34876242
[TBL] [Abstract][Full Text] [Related]
26. Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England.
Mason TFD; Whitston M; Hodgson J; Watkinson RE; Lau YS; Abdulrazeg O; Sutton M
BMC Med; 2021 Oct; 19(1):275. PubMed ID: 34663326
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021.
Xu S; Huang R; Sy LS; Glenn SC; Ryan DS; Morrissette K; Shay DK; Vazquez-Benitez G; Glanz JM; Klein NP; McClure D; Liles EG; Weintraub ES; Tseng HF; Qian L
MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(43):1520-1524. PubMed ID: 34710075
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
[TBL] [Abstract][Full Text] [Related]
30. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies.
Pormohammad A; Zarei M; Ghorbani S; Mohammadi M; Aghayari Sheikh Neshin S; Khatami A; Turner DL; Djalalinia S; Mousavi SA; Mardani-Fard HA; Kasaeian A; Turner RJ
Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062684
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study.
Bruxvoort KJ; Sy LS; Qian L; Ackerson BK; Luo Y; Lee GS; Tian Y; Florea A; Takhar HS; Tubert JE; Talarico CA; Tseng HF
Lancet Reg Health Am; 2022 Feb; 6():100134. PubMed ID: 34849505
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England.
Clifford S; Waight P; Hackman J; Hué S; Gower CM; Kirsebom FC; Skarnes C; Letley L; Lopez Bernal J; Andrews N; Flasche S; Miller E
Wellcome Open Res; 2023; 8():96. PubMed ID: 38058535
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study.
Shurrab FM; Al-Sadeq DW; Abou-Saleh H; Al-Dewik N; Elsharafi AE; Hamaydeh FM; Halawa BYA; Jamaleddin TM; Hameed HMA; Nizamuddin PB; Amanullah FH; Daas HI; Abu-Raddad LJ; Nasrallah GK
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214650
[TBL] [Abstract][Full Text] [Related]
36. Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan.
Naito T; Yan Y; Tabe Y; Seyama K; Deshpande GA
Hum Vaccin Immunother; 2022 Dec; 18(1):1-2. PubMed ID: 34614387
[TBL] [Abstract][Full Text] [Related]
37. Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.
Al-Sadeq DW; Shurrab FM; Ismail A; Amanullah FH; Thomas S; Aldewik N; Yassine HM; Abdul Rahim HF; Abu-Raddad L; Nasrallah GK
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34888670
[TBL] [Abstract][Full Text] [Related]
38. Durability analysis of the highly effective BNT162b2 vaccine against COVID-19.
Puranik A; Lenehan PJ; O'Horo JC; Pawlowski C; Niesen MJM; Virk A; Swift MD; Kremers W; Venkatakrishnan AJ; Gordon JE; Geyer HL; Speicher LL; Soundararajan V; Badley AD
PNAS Nexus; 2022 Jul; 1(3):pgac082. PubMed ID: 35832867
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household.
Yi S; Kim JM; Choe YJ; Hong S; Choi S; Ahn SB; Kim M; Park YJ
J Korean Med Sci; 2022 Jan; 37(1):e12. PubMed ID: 34981682
[TBL] [Abstract][Full Text] [Related]
40. The Impact of SARS-CoV-2 Primary Vaccination in a Cohort of Patients Hospitalized for Acute COVID-19 during Delta Variant Predominance.
Stupica D; Collinet-Adler S; Kejžar N; Jagodic Z; Poljak M; Nahtigal Klevišar M
J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
